TB-500 Spray (5MG)

TB-500 in pre-reconstituted intranasal spray format — the same Thymosin Beta-4 active fragment 17-23 reference peptide as our 5mg lyophilized standard, supplied in a metered-dose vial for laboratory protocols where on-site reconstitution is impractical.

Format rationale

Intranasal-format references are convenient in research panels where multiple reference peptides are screened simultaneously and reconstitution overhead becomes a workflow bottleneck. The TB-500 spray retains the same Fmoc-SPPS-synthesized 17-23 thymosin-β-4 fragment as the standard lyophilized form, pre-dissolved in a pH-buffered isotonic vehicle.

Synthesis & verification

The active fragment Ac-LKKTETQ-OH is produced by solid-phase peptide synthesis using Fmoc protecting-group strategy in a U.S.-based ISO 9001:2008 facility, then verified post-formulation for identity (LC-MS), purity (reverse-phase HPLC-UV ≥99.0%), and concentration. Each lot ships with its signed Certificate of Analysis. The COA reading guide walks through every line.

Storage & handling

Pre-reconstituted vials remain stable at 2-8 °C in original packaging for the printed shelf life. Protect from light, avoid freeze-thaw, and store upright. Spray valves are factory-calibrated for vertical orientation; inverted handling reduces metered accuracy.

Why BioFusion

Spray-format peptide references can drift over storage if formulated by suppliers without internal stability data. BioFusion’s spray vials are verified at formulation and re-verified at release. Batch transparency ledger shows every released lot. Bulk discounts trigger at three+ vials; members save 25% plus free U.S. shipping for 365 days.

For research and laboratory use only. This product is not a drug, food, or cosmetic, and is not intended for diagnostic, therapeutic, or in vivo human use.